Abstract. The pleiotropic cytokine interleukin 1 (IL-1) is considered to be the principal inducer of mediators of cartilage degradation in both, osteoarthritis (OA) and rheumatoid arthritis (RA). IL-1 activates numerous signaling pathways involved in cartilage destruction and dedifferentiation of chondrocytes. In this study, we analyzed expression and functional effects of IL-1 in human chondrocytes. We found an IL-1-induced reduction in the expression of the cartilage specific proteoglycan aggrecan as an indicator for the IL-1-mediated dedifferentiation of chondrocytes. To block the IL-1-induced signaling pathways specifically, we incubated human chondrocytes and cartilage explants with IL-1 in the presence of different signal transduction inhibitors and analyzed their effect on aggrecan mRNA expression and IL-6 secretion. IL-6 has been found to act synergistically in the IL-1-induced suppression of the proteoglycan synthesis in chondrocytes. Our results led to the identification of p38MAPK and/or PI3K/JNK as being crucial for IL-1-induced IL-6 secretion by chondrocytes. IL-1-induced down-regulation of aggrecan expression was found to be mediated by p38MAPK and/or ERK1/2. The identification and characterization of these signaling pathways will enable us to develop new modulation strategies for therapeutic use in inflammatory joint diseases.
Introduction
Cartilage plays a crucial role in maintaining joint functions, since it acts as a shock absorber during joint loading and motion. Extracellular matrix molecules including aggrecan and collagen type II provide the structural basis for this shock-absorbing function. Chronic joint inflammation and concurrent joint erosion and destruction are the main features of inflammatory joint diseases leading to a loss of joint function as a result of proteolytic cleavage of matrix molecules such as collagen type II and aggrecan (for review see refs. 1, 2) .
Numerous studies based on various animal models of arthritis have investigated the relative importance of IL-1 in the process of inflammation and destruction (3) . IL-1 plays a pivotal role in the destructive processes of arthritis, presumably due to its potent inhibitory effect on tissue repair. One further explanation for its deleterious effect in arthritis might be the induction of chondrocyte dedifferentiation. IL-1 is a pleiotropic cytokine and is considered to be the principal inducer of cartilage-degrading mediators in both, osteoarthritis (OA) and rheumatoid arthritis (RA) (1) . The contribution of IL-1 to arthritis and cartilage degradation is supported by the finding that the synovial fluid of arthritis patients contains elevated levels of IL-1 (4) . IL-1 is produced by cells in the arthritic joint including chondrocytes, fibroblasts, macrophages and bone-lining cells. The two agonists, IL-1· and IL-1ß bind to a specific plasma membrane receptor, the IL-1 receptor type I (IL-1RI). A third ligand, IL-1Ra, of which three intracellular isoforms exist, binds to IL-1RI and acts as a true receptor antagonist. Signaling via IL-1RI requires expression of the co-receptor molecule, IL-1 receptor accessory protein (IL1RAcP) (5) that has been found as being essential for IL-1 signaling (6) (7) (8) . A second receptor, the IL-1 receptor type II (IL-1RII), is thought to act as a decoy receptor serving as a ligand sink and competing for IL-1 and IL-1RAcP with IL-1RI (9, 10) . After binding to IL-1RI, IL-1 activates numerous signaling pathways culminating in the activation of NF-κB, mitogen-activated protein kinase (MAPK) p38, extracellular signal-regulated kinases p42/p44 (ERK1/2), c-Jun N-terminal kinase (JNK) and phosphatidylinositol 3-kinase (PI3K) (11, 12) . Signaling via p38MAPK and JNK appears to be the most relevant mechanism for the expression of IL-1-induced catabolic mediators in arthritis as it is involved in the induction of several matrix metalloproteinases degrading proteglycans and collagen type II in cartilage (13, 14) . The cytokine also inhibits the synthesis of new matrix proteins in cartilage p38MAPK mediates IL-1-induced down-regulation of aggrecan gene expression in human chondrocytes including aggrecan and the proliferation of chondrocytes which are necessary for cartilage repair (15, 16) . In this context, an essential synergistical role was claimed for IL-6 in the IL-1-induced suppression of proteoglycan synthesis (17) . It is generally accepted that IL-1 is a potent inducer of IL-6 production in primary cells and cell lines of articular tissues (18) (19) (20) . In order to eliminate negative effects of IL-1 on cartilage, we aimed to analyze signal transduction pathways potentially affecting cartilage integrity and chondrocyte differentiation. Our data provide evidence that specific inhibition of defined pathways reduces IL-1-mediated chondrocytic dedifferentiation.
Materials and methods

Preparation of cartilage explants and human chondrocytes.
For the study of healthy tissue, human cartilage was taken from the humeral heads of corpses during autopsy within 16 h of death after obtaining approval from the local ethics committee. Cartilage from seven donors (all male; mean ± SEM age 42±2.8 years) without any evidence of macroscopic articular degeneration was used for explant culture. Intact cartilage was cut into 200 mg slices and incubated at 37˚C and 10% CO 2 in Ham's F-12/DMEM (1:1) medium supplemented with 1 μg/ml amphotericine B (Bristol-Myers Scribb, München, Germany), FCS, vitamins and antibiotics for the indicated time in the presence or absence of recombinant (r) human (h) IL-1· after preincubation with or without distinct signaling inhibitors. Chondrocytes were prepared from normal cartilage samples by enzymatic digestion essentially as previously described (21) . Isolated chondrocytes were plated in 75-cm 2 tissue culture flasks in Ham's F-12/DMEM (1:1) supplemented with 10% FCS, MEM vitamins, 100 μg/ml streptomycin, and 100 U/ml penicillin and cultured at 37˚C in humidified air with 10% CO 2 for a maximum of two passages.
Cell culture. Peripheral blood mononuclear cells (PBMNC) were separated by leukapheresis of healthy donors followed by density gradient centrifugation over Ficoll/Hypaque. Isolated PBMNC were cultured in RPMI-1640 medium (PAN Biotech GmbH, Aidenbach, Germany) in the presence of 2% human pooled AB-group serum and 5x10 -8 M ß-mercaptoethanol supplemented with vitamins, sodium pyruvate, and nonessential amino acids (all from PAA Laboratories, Linz, Austria). For stimulation, cells were co-cultered with 100 ng/ ml LPS, 20 ng/ml PMA and 10 nM ionomycin (all from Sigma-Aldrich, Deisenhofen, Germany). Human chondrosarcoma cells SW1353 were cultured in Ham's F-12/DMEM (1:1) supplemented with 10% FCS, MEM vitamins, 100 μg/ml streptomycin, and 100 U/ml penicillin and cultured at 37˚C in humidified air with 10% CO 2 . Mouse thymoma cells EL4/5D3 were cultured in RPMI-1640 medium containing 2 mM glutamine, 10% FCS, and 30 μM ß-mercaptoethanol at 37˚C in humidified air with 5% CO 2 . rhIL-1· was purchased from PAN Biotech GmbH. The c-Jun N-terminal kinase (JNK) inhibitor SP600125 was obtained from Biomol GmbH (Hamburg, Germany). Inhibitors for ERK1/2 (PD98059) and p38MAPK (SB203580) were provided by Calbiochem (Darmstadt, Germany). The PI3K inhibitor LY294002 was obtained from New England Biolabs GmbH (Frankfurt, Germany). Stock solutions were prepared in DMSO and stored at -20˚C. Serial dilutions were made in culture medium containing FCS. For stimulation, 6.5x10 4 cells (SW1353 and primary chondrocytes) were seeded in 6-well plates until a confluency of 80% was reached. Afterwards, cells were stimulated with 10 U/ml rhIL-1· for 24-48 h. Inhibitors were added 2 h prior to IL-1 incubation; the DMSO concentration within each sample including negative controls was adjusted equally. Functionality of the inhibitors was confirmed by analyzing the inhibitory capacities of PD98059, SB203580, and SP600125 on IL-2 secretion by mouse thymoma cells EL4/ 5D3 in a concentration-dependent manner. From these studies, we calculated the following IC 50 values: PD98059 (50 μM), SB203580 (37.5 μM), SP600125 (25 μM). Functionality of the PI3K inhibitor LY294002 was evaluated by Western blotting using anti-phospho-Akt antibodies (New England Biolabs GmbH) and lysates from human melanoma and SW1353 cells. None of the inhibitors displayed any cytotoxic effect at the concentrations used.
RNA extraction. Human cartilage explants were frozen in liquid N 2 and ground in a laboratory ball mill (Mikro-Dismembrator S; B. Braun, Melsungen, Germany). Total cellular RNA was isolated from different sources using the RNeasy ® spin column purification kit (Qiagen, Hilden, Germany). RNA concentrations were measured using the RiboGreen ® RNA quantitation kit (Molecular Probes, Leiden, The Netherlands).
Reverse transcription and semi-quantitative PCR.
Reverse transcription (RT) was performed with 750 ng of total cellular RNA using the SuperScript™ II RNase H -reverse transcriptase (Invitrogen, Karlsruhe, Germany) in a total volume of 20 μl. After an initial heat inactivation for 10 min at 70˚C, firststrand cDNA synthesis was carried out with 500 ng random primer and 200 U SuperScript II for 50 min at 37˚C followed by heat inactivation at 70˚C for 10 min. PCR was performed in a total volume of 25 μl using 50 pmol of forward and reverse primers as given in Table I . After activating polymerase for 15 min at 95˚C, the cDNA was amplified by 25-35 cycles of 95˚C for 1 min, 55-65˚C for 1 min, and 72˚C for 1 min using the HotStarTaq™ Master Mix kit (Qiagen) followed by a final extension period of 10 min at 72˚C. IL-1RI cDNA was specifically amplified using 0.6 U of HotStarTaq™ DNA polymerase (Qiagen) in the presence of 3 mM MgCl 2 under the conditions mentioned above. In contrast, aggrecan cDNA was amplified with 1.5 mM MgCl 2 and a 5-min extension period at 72˚C. PCR products were resolved on 1.2% agarose gels and visualized by staining with ethidium bromide and UV transillumination.
Analysis of mRNA expression by quantitative PCR.
Quantitative real-time PCR was performed using a LightCycler (Roche, Mannheim, Germany). 2 μl cDNA template, 2 μl 25 mM MgCl 2 , 0.5 μM of forward and reverse primers (Table I ) and 2 μl of SybrGreen LightCycler Mix in a total of 20 μl were applied to the following PCR program: 30 sec 95˚C (initial denaturation); 20˚C/sec temperature transition rate up to 95˚C for 15 sec, 3 sec 65˚C, 5 sec 72˚C, 81˚C acquisition mode single, repeated for 40 times (amplification). The PCR was evaluated by melting curve analysis and checking the PCR products on 1.0% agarose gels. Expression levels were calculated using the LightCycler software (Roche) and standardized to GAPDH.
Cytokine assays. Concentrations of IL-6 in the cell culture supernatants were evaluated by sandwich-ELISA (BD Biosciences, Erembodegem, Belgium) measuring serial dilutions of supernatants from IL-1-treated or -untreated cells in the presence or absence of certain inhibitors. IL-2 secretion by mouse thymoma EL4/5D3 cells was quantified as previously described (7).
Flow cytometry. For flow cytometry analysis, 1.5-2x10 5 cells were stained for 1 h at 0˚C in the dark, either with 1 μg/ml of biotinylated anti-IL-1RAcP or unconjugated anti-IL-1RI (both from R&D Systems, Wiesbaden, Germany) or anti-IL-1RAcP (ProSci Inc., Poway, CA, USA). After washing, cells were incubated with 5 μl of biotinylated anti-rabbit IgG (Dako, Glostrup, Denmark) as secondary antibody for a further 1 h followed by a final 1-h incubation in the presence of 10 μl FITC-labelled avidin (R&D Systems). In the case of biotinylated IL-1RAcP, cells were directly stained with FITCconjugated avidin. Surface expression was then measured in comparison to an isotype-matched control sample using a Coulter ® EPICS™ XL flow cytometer (Beckman Coulter GmbH, Krefeld, Germany). The fluorescence histograms were generated using gated data.
Statistical analysis. Statistical differences between mean values were analyzed using the two-sided Student's t-test. Differences were considered as significant for p<0.05.
Results
Expression of IL-1 isoforms and receptors in human chondrocytes.
Firstly, we analyzed human primary chondrocytes from healthy donors and the human chondrosarcoma cell line SW1353 with regard to the expression of several components of the IL-1 signaling pathway. As a positive control, we used stimulated human PBMNC known to express several IL-1 family members. Using semi-quantitative RT-PCR, constitutive expression of IL-1RI, IL-1RAcP, and IL-1ß was found. In Table I . Primer sets, annealing temperature, and cycle number used for polymerase chain reaction. 
contrast to SW1353 cells, human primary chondrocytes did not express any detectable mRNA of IL-1·, neither constitutively nor after IL-1 stimulation. Moreover, no mRNA of the antiinflammatory components IL-1RII and soluble IL-1Ra was detectable in both, SW1353 and primary chondrocytes in the presence or absence of IL-1 (Fig. 1) . Accordingly, neither variant of two intracellular isoforms of IL-1Ra (icIL-1Ra1 and icIL-1Ra2) could be detected (data not shown). We additionally analyzed IL-1RI and IL-1RAcP on the protein level by flow cytometry and observed a weak surface display of both receptor chains in SW1353 cells. A surface display of the same order of magnitude was also found in the IL-1 highly responsive mouse thymoma cell line EL4/5D3 (Fig. 2) that was reported to carry high numbers of IL-1 receptors type I in comparison to other cell types (6) . Nevertheless, a low number of IL-1RI molecules (<10) is sufficient for initiation of the IL-1 signaling cascade providing complete IL-1 responsiveness (22) .
Effect of IL-1 on chondrocytes. As published previously, IL-1 is expected to have a dedifferentiating effect on chondrocytes (23, 24) . To analyze whether this effect is repressable, we treated SW1353 cells with IL-1 in the presence or absence of inhibitors of the ERK1/2 (PD98059), p38MAPK (SB203580), PI3K (LY294002) or JNK pathway (SP600125) and analyzed changes in the expression level of aggrecan by quantitative RT-PCR. Aggrecan is known to be a specific marker of differentiated chondrocytes (25) . As demonstrated in Fig. 3 , IL-1 induced a strong down-regulation of the aggrecan expression of approximately 65% compared to untreated controls. Only inhibition of p38MAPK by SB203580 and inhibition of ERK1/2 by PD98059 led to an almost complete preservation of the marker molecule, whereas inhibition of Figure 1 . Expression of several members of the IL-1 family in human chondrocytes and PBMNC. Human chondrosarcoma cells SW1353 and human primary chondrocytes from healthy donors were cultured in the presence or absence of 10 U/ml rhIL-1· for 24 h, whereas human PBMNC were costimulated with 100 ng/ml LPS, 20 ng/ml PMA, and 10 nM ionomycin for 4 h. Total RNA was prepared and reverse transcribed followed by semiquantitative RT-PCR and agarose gel-electrophoresis including the negative control (Ctrl.). JNK by SP600125 and PI3K by LY294002 was without any effect. In contrast to the p38MAPK inhibitor SB203580, incubation of SW1353 with PD98059, SP600125 or LY294002 alone down-regulated the constitutive aggrecan mRNA expression. From these results we conclude that p38MAPK and ERK1/2 play crucial roles in the specific IL-1-mediated down-regulation of the aggrecan expression in SW1353.
Blockage of IL-1 effects. The aim of this study was to block specifically the IL-1-triggered pathways regulating the dedifferentiation of chondrocytes. We therefore treated SW1353 cells with distinct signaling inhibitors prior to IL-1 stimulation and analyzed IL-6 secretion into the supernatants, because IL-6 is supposed to act synergistically in the IL-1-induced suppression of proteoglycan synthesis (17) . IL-1 strongly induced secretion of IL-6 by SW1353 cells thus confirming previous results (19) . Only SB203580, the inhibitor of p38MAPK, as well as the PI3K inhibitor LY294002 were able to abolish induction of IL-6 (Fig. 4) .
To analyze whether this inhibition is transferable to the ex vivo situation we performed the identical experiment using slices of human cartilage from seven healthy donors. As given in Fig. 5 , we found a rapid and strong induction of IL-6 in explants of human cartilage within 24 h of incubation with IL-1 independent of the donor material. This cytokine secretion was completely blockable by SB203580 implying a critical contribution of the p38MAPK signaling pathway. Furthermore, the JNK inhibitor SP600125 was effective to a similar degree as it also blocked the IL-1-induced IL-6 production by human cartilage explants. Minor effects were also seen in the presence of the ERK1/2 inhibitor, PD98059 (Fig. 5) .
Analysis of regulation of aggrecan expression was performed by quantitative real-time PCR (Fig. 6) . In 4 of 7 cases, human cartilage explants showed a massive down-regulation of the aggrecan mRNA expression after IL-1 stimulation. No alteration of the aggrecan mRNA expression was noted in the 3 other cases upon IL-1 exposure. Interestingly, IL-1-induced IL-6 production and its affection by signal transduction inhibitors did not differ between the responder and nonresponder group (data not shown). Apart from ERK1/2, we identified p38MAPK as playing a crucial role in mediating IL-1-induced down-regulation of aggrecan in SW1353 cells. We therefore analyzed a possible protective effect of the p38MAPK inhibitor SB203580 and the ERK1/2 inhibitor PD98059 in the responder group. As demonstrated in Fig. 6 , IL-1 induced a massive down-regulation of the aggrecan expression to 12% of the untreated controls in human cartilage explants. This down-regulation was prevented by SB203580, whereas PD98059 had no effect. Fig. 3 . IL-6 secretion into the supernatants was analyzed after 24 h by sandwich-ELISA. Data represent means ± SEM from six separate experiments performed in triplicates. IL-6 production of IL-1-treated cells was set as 100%. * p<0.001 compared to IL-1-treated cells. IL-6 release after incubation with the inhibitor alone was negligible and in the same range as the untreated controls. Figure 5 . Effect of IL-1 on IL-6 production in human cartilage explants. Human cartilage from healthy donors was cut into 200 mg slices and incubated in the presence or absence of IL-1 with or without distinct signaling inhibitors as mentioned above. IL-6 production was determined after 24 h by sandwich-ELISA. IL-6 production of IL-1-treated explants was set as 100%. Data represent means ± SEM from seven separate experiments performed in triplicates. * p<0.05; ** p<0.0001 compared to IL-1-treated cells. IL-6 release after incubation with the inhibitor alone was in the same range as the untreated controls. Figure 6 . Inhibition of p38MAPK protects human cartilage from IL-1-induced down-regulation of aggrecan mRNA expression. Human cartilage explants from healthy donors were prepared and incubated with or without 10 U/ml rhIL-1· in the presence or absence of 10 μM SB203580 (SB) and 10 μM PD98059 (PD), respectively. Aggrecan mRNA expression was analyzed after 48 h by quantitative RT-PCR. Aggrecan expression of the untreated controls was set as 100%. Data represent means ± SEM from four separate experiments performed in triplicates. * p<0.05 compared to IL-1-treated cells; ** p<0.0001 compared to control.
Discussion
The aim of this study was to identify the IL-1-triggered pathways regulating the dedifferentiation of chondrocytes. For these studies, the human chondrosarcoma cell line SW1353 and human cartilage explants were chosen. SW1353 cells have been used previously by our group as a reliable substitute for primary human chondrocytes regarding the study of IL-1-mediated protease and pro-inflammatory cytokine production and the signaling pathways involved (26) . Initial expression studies with SW1353 cells and human primary chondrocytes revealed a constitutive expression of the pro-inflammatory constituents of the IL-1 receptor/ligand family. Expression of IL-1· could not be detected in isolated primary chondrocytes from healthy donors, neither constitutively nor after stimulation with IL-1. The two structurally related cytokines, IL-1· and IL-1ß, are agonists which induce identical responses by binding IL-1RI with high affinity (27) . On the other hand, they differ remarkably with respect to regulation of gene expression, mRNA stability, translation, processing and secretion (28) which might be responsible for the differences in IL-1· mRNA expression mentioned above. In order to gain insight into the signaling pathways involved in chondrocyte dedifferentiation, we used several pharmacological signal transduction inhibitors and analyzed their effect on the IL-1 response in human chondrocytes. We found a down-regulation of the chondrocyte differentiation marker aggrecan induced by IL-1. This observation is consistent with the results of previous studies indicating that IL-1 downregulates the major anabolic genes in articular chondrocytes including type II collagen and aggrecan (29) (30) (31) (32) . Inhibition of p38MAPK protected both, human chondrosarcoma cells and cartilage explants from IL-1-mediated down-regulation of aggrecan suggesting a pivotal role of this kinase in mediating the effects of IL-1 on anabolic gene expression in normal articular chondrocytes. Whereas inhibition of the ERK1/2 pathway was also effective in avoiding IL-1-induced downregulation of aggrecan in chondrosarcoma cells, this effect could not be observed in human cartilage indicating differences in the mechanism of IL-1-mediated effects on matrix molecules in chondrosarcoma cells and primary chondrocytes in the cartilage experiment. An interesting finding was that in contrast to p38MAPK inhibition by SB203580, inhibition of the PI3K and JNK pathway by LY294002 and SP600125, respectively, down-regulated the constitutive aggrecan expression in SW1353 cells suggesting a possible role of these signaling pathways in the homeostatic regulation of aggrecan expression but also preventing a conclusion with respect to an IL-1-specific component in these pathways. Although the ERK1/2 inhibitor PD98059 showed a minor suppressive effect on the constitutive aggrecan mRNA expression, it significantly counteracted IL-1-induced suppression indicating its participitation in the IL-1-specific effects.
We also analyzed the signaling pathways involved in IL-1-induced secretion of the pro-inflammatory cytokine IL-6 in human chondrocytes using the selected inhibitors. One of them, SB203580, functions as a selective inhibitor of p38MAPK only when used at low concentrations (≤1 μM). In contrast, high concentrations of SB203580 (10-25 μM) such as we have used inhibit both, p38MAPK and JNK (33) . Since in our system the JNK inhibitor SP600125 did not exert any inhibitory effect on IL-1-induced IL-6 secretion by SW1353, while SB203580 was strongly effective, we conclude that this effect was mediated by p38MAPK inhibition. Pretreatment of SW1353 with LY294002 also blocked IL-1-induced IL-6 secretion significantly. Under these conditions (50 μM) it selectively abolishes PI3K activity without inhibiting other kinases including PKC and MAPK (34) . The results were confirmed in ex vivo experiments. Human cartilage explants from healthy donors showed a suppression of IL-1-induced IL-6 secretion after co-incubation with inhibitors of p38MAPK and JNK. These observations extend previous findings demonstrating a critical involvement of the ERK, p38MAPK, and NF-κB pathway in IL-1ß-mediated IL-6 mRNA expression in normal human articular chondrocytes (35) . In contrast, our inhibitor studies in the human chondrosarcoma cell line SW1353 also demonstrated a role of PI3K in mediating IL-1-induced IL-6 secretion reflecting peculiarities of these tumor cells or influence of the microenvironment in cartilage. Taking into consideration the putative synergistical role of IL-6 in IL-1-induced suppression of proteoglycan synthesis in explants of human articular cartilage (17) and the suppressive effect of IL-6/sIL-6R complexes on the aggrecan core expression in isolated bovine articular chondrocytes (36), we hypothesize that chondrocyte dedifferentiation induced by IL-1 might also be mediated indirectly -at least in part -by IL-6 via the signaling pathways identified so far.
It has been shown previously that activation of the p38MAPK pathway induces markers of terminal chondrocyte differentiation not only in chondrocytes from different species (37) but also in human synovial fibroblasts (38) . From these results we hypothesize that p38MAPK represents a critical signaling molecule mediating both, chondrogenic differentiation and dedifferentiation processes in articular cells. p38MAPK activity also modulates proliferation of rabbit articular chondrocytes under basal and IL-1-activated conditions (39) . Apart from JNK, signal transduction via p38MAPK appears to represent the most important mechanism for the expression of IL-1-induced mediators (13, 14) . Our own findings suggest a pivotal role for p38MAPK in mediating IL-1-induced down-regulation of the aggrecan gene expression in human chondrocytes. A recent publication reports on a protective effect of antagonists of IL-1 on the glycosaminoglycan content and aggrecan expression in cartilage explants from OA patients (40) . According to our own results, these observations were found to be strictly donor-dependent.
The ability to block the IL-1 signaling cascade to enhance aggrecan expression in cartilage from certain donors is of interest in view of the demonstrated inhibitory effect of this cytokine on the synthesis of matrix molecules. From these data one can speculate that, at least in some cases, blockage of the IL-1 signaling pathway may have the potential to promote cartilage repair by inhibiting aggrecan degradation. The reason why some donor tissue did not respond to IL-1 with the expected down-regulation of the aggrecan expression remains to be elucidated. Gender-specific effects can most likely be excluded, since the cartilage used was exclusively gained from male corpses rendering the sample collective distinctly homogeneous. The contrasting responses might be due to differences in the activation status of the cartilage explants. Is has been shown previously that explantation and cutting of porcine articular cartilage activates intracellular inflammatory signaling pathways and induces IL-1· mRNA expression (41) . This might lead to a strong pre-stimulation with IL-1 abolishing certain further in vitro effects of the cytokine. As a result, cartilage may become hyporesponsive to catabolic factors such as IL-1 with respect to matrix molecule expression.
In conclusion, in the present study we identified a central role of p38MAPK in mediating IL-1-induced catabolic effects in human chondrocytes. The p38MAPK inhibitor SB203580 was found to antagonize IL-1-mediated downregulation of gene expression of the matrix molecule aggrecan. Although this effect is restricted to a certain donor collective, the identification and characterization of these signaling pathways might enable us to develop new modulation strategies for therapeutic use in inflammatory joint diseases. Interestingly, oral treatment with selective inhibitors of PI3KÁ was found to suppress joint inflammation and damage in mouse models of RA (42) rendering blockage of certain signal transduction pathways a promising tool as potential therapeutic intervention for the treatment of chronic inflammatory disorders.
